Goat F(ab')2 Anti-Human Ig-FITC

Cat. No.
2012-02  
Size
0.5 mg  
Price (USD)
$75.00 
Specificity Reacts with the heavy and light chains of human IgG, IgM, and IgA
Source Pepsin digest of Goat Anti-Human Ig (SB Cat. No. 2010)
Cross Adsorption None; may react with immunoglobulins from other species
Isotype Goat F(ab')2 IgG
Isotype Control Goat F(ab')2 IgG-FITC
Format/Conjugate FITC (Fluorescein)
Buffer Formulation Phosphate buffered saline containing 0.1% sodium azide
Concentration 0.5 mg/mL
Volume 1.0 mL
Storage & Handling 2-8°C; Avoid exposure to light
Please refer to product specific SDS
Applications
Quality tested applications for relevant formats include -
ELISA 1,2,5
FLISA
Flow Cytometry 7,8
Other referenced applications for relevant formats include -
ELISpot 3,4
Immunohistochemistry-Frozen Sections 6
Stimulation 9,10
Recommended Dilutions Please refer to product specific Technical Bulletin
RRID AB_2795573
  • Human peripheral blood lymphocytes were stained with Goat F(ab’)2 Anti-Human Ig-FITC (SB Cat. No. 2012-02) and Mouse Anti-Human CD19-PE (SB Cat. No. 9340-09).

Human peripheral blood lymphocytes were stained with Goat F(ab’)2 Anti-Human Ig-FITC (SB Cat. No. 2012-02) and Mouse Anti-Human CD19-PE (SB Cat. No. 9340-09).
 
Related Products (11)
References
1. Kozlowski PA, Chen D, Eldridge JH, Jackson S. Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals. AIDS Res Hum Retroviruses. 1994;10:813-22. (ELISA)
2. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA. 2006;103:17408-13. (ELISA)
3. Sira MM, Yoshida T, Takeuchi M, Kashiwayama Y, Futatani T, Kanegane H, et al. A novel immunoregulatory protein in human colostrum, syntenin-1, for promoting the development of IgA-producing cells from cord blood B cells. Int Immunol. 2009;21:1013-23. (ELISpot)
4. Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11(4):R123. (ELISpot)
5. White CA, Pone EJ, Lam T, Tat C, Hayama KL, Li G, et al. Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses. J Immunol. 2014;193:5933-50. (ELISA)
6. Xu W, He B, Chiu A, Chadburn A, Shan M, Buldys M, et al. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol. 2007;8:294-303. (IHC-FS)
7. Heile JM, Fong Y, Rosa D, Berger K, Saletti G, Campagnoli S, et al. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates. J Virol. 2000;74:6885-92. (FC)
8. Bao G, Li Y, Ma Q, He X, Xing J, Yang X, et al. Isolating human antibody against human hepatocellular carcinoma by guided-selection. Cancer Biol Ther. 2005;4:1374-80. (FC)
9. Liubchenko GA, Appleberry HC, Striebich CC, Franklin KE, Derber LA, Holers VM, et al. Rheumatoid arthritis is associated with signaling alterations in naturally occurring autoreactive B-lymphocytes. J Autoimmun. 2013;40:111-21. (Stim)
10. Lyubchenko T, Zerbe GO. B cell receptor signaling-based index as a biomarker for the loss of peripheral immune tolerance in autoreactive B cells in rheumatoid arthritis. PLoS One. 2014;9(7):e102128. (Stim)